Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 9, 2021updated 07 Jan 2022 6:45am

ICR says cancer trial enrolment drops during Covid-19 pandemic

Administrative burden, insufficient data are some of the issues identified by ICR for the decrease in recruitment.

The Institute of Cancer Research (ICR), London, in the UK has reported that the number of individuals with cancer entering clinical trials has dropped during the Covid-19 pandemic.

Estimates show that the 60% reduction in recruitment to cancer trials was noted during the first year of the pandemic.

In 2020-2021, the number of individuals with cancer enrolled into trials in England dropped to 27,734 from an average of 67,057 over the previous three years, the National Institute for Health Research (NIHR) figures showed.

These figures come amid warnings that the pandemic has intensified enduring problems with funding for trials, regulation and access.

A study conducted from April to July 2020 during the initial stages of the pandemic found that greater administrative burden in launching trials, specifically for novel trial designs such as biomarker-driven studies for precision therapeutic, led to reduced recruitment.

Other issues included the UK National Health Service not having mechanisms to perform quick genetic testing for patients to recruit them for precision therapy trials.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Furthermore, funding for doctors to conduct clinical research differs and insufficient data on trials are available to patients and doctors.

The ICR further added that there is a disparity to access trials throughout the country, with some patients in rural regions reporting travelling more than 100 miles to receive a trial treatment.

ICR chief executive professor Kristian Helin said: “Clinical trials have huge benefits for patients, both by providing access to the latest drugs and technologies and by demonstrating the effectiveness of the next generation of treatments for use on the NHS.

“We would like to see a clinical trial being made available for every cancer patient who would like to participate in one.

“That requires both investment in Covid-19 clinical research recovery, to get us back to where we were before the pandemic, and broader measures to widen access to trials by reshaping funding, regulation, information and treatment pathways.”

This October, the ICR reported that a cocktail of immunotherapies could be effective as first-line therapy to treat relapsed or metastatic head and neck cancer patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy